Germline Predisposition in Pediatric Central Nervous System Tumors: Insights from a Multigene Panel Study
Oncology Research · 2026
DOI: 10.32604/or.2026.079120 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncology Research, 2026. Verfasst von Meerim Park und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Center for Pediatric Cancer, National Cancer Center, Goyang, Republic of Korea. Hauptthemen laut MEDLINE: Germ-Line Mutation, Genetic Predisposition to Disease, Central Nervous System Neoplasms, Biomarkers, Tumor. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Objectives
Germline variants in cancer predisposition genes have been increasingly recognized in pediatric cancers. However, their spectrum in East Asian children with central nervous system (CNS) tumors remains insufficiently defined. This study investigated the prevalence and clinical significance of pathogenic or likely pathogenic (P/LP) germline mutations in Korean children, adolescents, and young adults (AYAs) with CNS tumors.
Methods
We performed targeted next-generation sequencing of 358 cancer-associated genes using peripheral blood DNA from 108 patients. Germline variants were classified according to ACMG/AMP guidelines and curated using ClinVar and relevant literature.
Results
Among 108 patients, 17 (15.7%) carried P/LP germline variants. The median age at diagnosis was 7.7 years (range, 1.0-24.0), and 64.7% were male. P/LP variants were most frequent in other CNS tumors (4/11, 36.4%), including 2 glioneuronal tumors, 1 schwannoma, 1 atypical teratoid rhabdoid tumor (ATRT), and gliomas (9/32, 28.1%), followed by medulloblastomas (3/31, 9.7%). In gliomas, P/LP variants in MLH1, NF1, MUTYH, PALB2, PMS2, FANCM, and TP53 were observed, while medulloblastomas carried alterations in SUFU, BRIP1, and FANCI. SMARCB1 variant was found in ATRT. Among 25 patients with intracranial germ cell tumors, only a single case carried a P/LP germline variant, identified in FANCI.
Conclusion
Germline P/LP mutations were identified in 15.7% of Korean children and AYAs with CNS tumors, most commonly in gliomas and other CNS tumors. Our findings highlight the molecular heterogeneity of germline predisposition in CNS tumors and emphasize the importance of germline testing for risk assessment and surveillance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Center for Pediatric Cancer, National Cancer Center, Goyang, Republic of Korea.
- Department of Laboratory Medicine, National Cancer Center, Goyang, Republic of Korea.
- Geninus Inc., BI Center, Seoul, Republic of Korea.
- NGS Research Center, Seegene Medical Foundation, Seoul, Republic of Korea.
- Department of Pathology, National Cancer Center, Goyang, Republic of Korea.
Zitieren
APA
Park, M., Park, S., Oh, E., Choi, J., Kwon, M. M., Park, S. Y., Lee, J. A., & Park, H. J. (2026). Germline Predisposition in Pediatric Central Nervous System Tumors: Insights from a Multigene Panel Study. Oncology Research. https://doi.org/10.32604/or.2026.079120
Vancouver
Park M, Park S, Oh E, Choi J, Kwon MM, Park SY, et al. Germline Predisposition in Pediatric Central Nervous System Tumors: Insights from a Multigene Panel Study. Oncology Research. 2026. doi:10.32604/or.2026.079120
BibTeX
@article{Park2026,
author = {Park, Meerim and Park, Seungman and Oh, Ensel and Choi, Jongmun and Kwon, Mi Mi and Park, Seog-Yun and Lee, Jun Ah and Park, Hyeon Jin},
title = {Germline Predisposition in Pediatric Central Nervous System Tumors: Insights from a Multigene Panel Study},
journal = {Oncology Research},
year = {2026},
doi = {10.32604/or.2026.079120}
}
EUVIMED